Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Jan;57(1):3–6. doi: 10.1136/jnnp.57.1.3

Immunotherapy for multiple sclerosis.

R A Hughes
PMCID: PMC485031  PMID: 8301302

Full text

PDF
3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese G., Gandolfo C., Loeb C. "Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci. 1983 Jun;4(2):169–172. doi: 10.1007/BF02043900. [DOI] [PubMed] [Google Scholar]
  2. Achiron A., Pras E., Gilad R., Ziv I., Mandel M., Gordon C. R., Noy S., Sarova-Pinhas I., Melamed E. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol. 1992 Dec;49(12):1233–1236. doi: 10.1001/archneur.1992.00530360031013. [DOI] [PubMed] [Google Scholar]
  3. Alam S. M., Kyriakides T., Lawden M., Newman P. K. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1219–1220. doi: 10.1136/jnnp.56.11.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Arnason B. G. Interferon beta in multiple sclerosis. Neurology. 1993 Apr;43(4):641–643. doi: 10.1212/wnl.43.4.641. [DOI] [PubMed] [Google Scholar]
  5. Barnes M. P., Bateman D. E., Cleland P. G., Dick D. J., Walls T. J., Newman P. K., Saunders M., Tilley P. J. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry. 1985 Feb;48(2):157–159. doi: 10.1136/jnnp.48.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Beck R. W., Cleary P. A., Anderson M. M., Jr, Keltner J. L., Shults W. T., Kaufman D. I., Buckley E. G., Corbett J. J., Kupersmith M. J., Miller N. R. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581–588. doi: 10.1056/NEJM199202273260901. [DOI] [PubMed] [Google Scholar]
  7. Bornstein M. B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheil-Smoller S., Spada V. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987 Aug 13;317(7):408–414. doi: 10.1056/NEJM198708133170703. [DOI] [PubMed] [Google Scholar]
  8. Bornstein M. B., Miller A., Slagle S., Weitzman M., Drexler E., Keilson M., Spada V., Weiss W., Appel S., Rolak L. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991 Apr;41(4):533–539. doi: 10.1212/wnl.41.4.533. [DOI] [PubMed] [Google Scholar]
  9. Camenga D. L., Johnson K. P., Alter M., Engelhardt C. D., Fishman P. S., Greenstein J. I., Haley A. S., Hirsch R. L., Kleiner J. E., Kofie V. Y. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol. 1986 Dec;43(12):1239–1246. doi: 10.1001/archneur.1986.00520120023011. [DOI] [PubMed] [Google Scholar]
  10. Carter J. L., Hafler D. A., Dawson D. M., Orav J., Weiner H. L. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 1988 Jul;38(7 Suppl 2):9–14. [PubMed] [Google Scholar]
  11. Cook S. D., Devereux C., Troiano R., Zito G., Hafstein M., Lavenhar M., Hernandez E., Dowling P. C. Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol. 1987 Nov;22(5):634–638. doi: 10.1002/ana.410220513. [DOI] [PubMed] [Google Scholar]
  12. Cook S. D., Troiano R., Zito G., Rohowsky-Kochan R., Sheffit C., Dowling P. C., Devereux C. K. Deaths after total lymphoid irradiation for multiple sclerosis. Lancet. 1989 Jul 29;2(8657):277–278. doi: 10.1016/s0140-6736(89)90463-7. [DOI] [PubMed] [Google Scholar]
  13. Edwards M. K., Farlow M. R., Stevens J. C. Multiple sclerosis: MRI and clinical correlation. AJR Am J Roentgenol. 1986 Sep;147(3):571–574. doi: 10.2214/ajr.147.3.571. [DOI] [PubMed] [Google Scholar]
  14. Gonzalez-Scarano F., Grossman R. I., Galetta S., Atlas S. W., Silberberg D. H. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol. 1987 Mar;21(3):300–306. doi: 10.1002/ana.410210312. [DOI] [PubMed] [Google Scholar]
  15. Hafler D. A., Cohen I., Benjamin D. S., Weiner H. L. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol. 1992 Mar;62(3):307–313. doi: 10.1016/0090-1229(92)90108-z. [DOI] [PubMed] [Google Scholar]
  16. Hafler D. A., Weiner H. L. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology. 1988 Jul;38(7 Suppl 2):42–47. [PubMed] [Google Scholar]
  17. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  18. Huber S. J., Paulson G. W., Chakeres D., Pakalnis A., Brogan M., Phillips B. L., Myers M. A., Rammohan K. W. Magnetic resonance imaging and clinical correlations in multiple sclerosis. J Neurol Sci. 1988 Aug;86(1):1–12. doi: 10.1016/0022-510x(88)90002-0. [DOI] [PubMed] [Google Scholar]
  19. Jacobs L., Salazar A. M., Herndon R., Reese P. A., Freeman A., Jozefowicz R., Cuetter A., Husain F., Smith W. A., Ekes R. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study. Arch Neurol. 1987 Jun;44(6):589–595. doi: 10.1001/archneur.1987.00520180013008. [DOI] [PubMed] [Google Scholar]
  20. Khatri B. O., McQuillen M. P., Harrington G. J., Schmoll D., Hoffmann R. G. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology. 1985 Mar;35(3):312–319. doi: 10.1212/wnl.35.3.312. [DOI] [PubMed] [Google Scholar]
  21. Kinlen L. J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. doi: 10.1016/0002-9343(85)90245-1. [DOI] [PubMed] [Google Scholar]
  22. Knobler R. L., Panitch H. S., Braheny S. L., Sipe J. C., Rice G. P., Huddlestone J. R., Francis G. S., Hooper C. K., Kamin-Lewis R. M., Johnson K. P. Systemic alpha-interferon therapy of multiple sclerosis. Neurology. 1984 Oct;34(10):1273–1279. doi: 10.1212/wnl.34.10.1273. [DOI] [PubMed] [Google Scholar]
  23. Kroemer G., Martínez C. Mechanisms of self tolerance. Immunol Today. 1992 Oct;13(10):401–404. doi: 10.1016/0167-5699(92)90090-t. [DOI] [PubMed] [Google Scholar]
  24. Likosky W. H., Fireman B., Elmore R., Eno G., Gale K., Goode G. B., Ikeda K., Laster J., Mosher C., Rozance J. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1055–1060. doi: 10.1136/jnnp.54.12.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. McFarland H. F., Frank J. A., Albert P. S., Smith M. E., Martin R., Harris J. O., Patronas N., Maloni H., McFarlin D. E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 Dec;32(6):758–766. doi: 10.1002/ana.410320609. [DOI] [PubMed] [Google Scholar]
  26. Milligan N. M., Newcombe R., Compston D. A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511–516. doi: 10.1136/jnnp.50.5.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Noronha A., Toscas A., Jensen M. A. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol. 1990 Feb;27(2):207–210. doi: 10.1002/ana.410270219. [DOI] [PubMed] [Google Scholar]
  28. Panitch H. S., Hirsch R. L., Haley A. S., Johnson K. P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987 Apr 18;1(8538):893–895. doi: 10.1016/s0140-6736(87)92863-7. [DOI] [PubMed] [Google Scholar]
  29. Panitch H. S. Interferons in multiple sclerosis. A review of the evidence. Drugs. 1992 Dec;44(6):946–962. doi: 10.2165/00003495-199244060-00004. [DOI] [PubMed] [Google Scholar]
  30. Paty D. W., Li D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
  31. Rose A. S., Kuzma J. W., Kurtzke J. F., Namerow N. S., Sibley W. A., Tourtellotte W. W. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report. Neurology. 1970 May;20(5):1–59. doi: 10.1212/wnl.20.5_part_2.1. [DOI] [PubMed] [Google Scholar]
  32. Rudge P., Koetsier J. C., Mertin J., Mispelblom Beyer J. O., Van Walbeek H. K., Clifford Jones R., Harrison J., Robinson K., Mellein B., Poole T. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989 May;52(5):559–565. doi: 10.1136/jnnp.52.5.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thompson A. J., Kennard C., Swash M., Summers B., Yuill G. M., Shepherd D. I., Roche S., Perkin G. D., Loizou L. A., Ferner R. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989 Jul;39(7):969–971. doi: 10.1212/wnl.39.7.969. [DOI] [PubMed] [Google Scholar]
  34. Truyen L., Gheuens J., Van de Vyver F. L., Parizel P. M., Peersman G. V., Martin J. J. Improved correlation of magnetic resonance imaging (MRI) with clinical status in multiple sclerosis (MS) by use of an extensive standardized imaging-protocol. J Neurol Sci. 1990 May;96(2-3):173–182. doi: 10.1016/0022-510x(90)90130-f. [DOI] [PubMed] [Google Scholar]
  35. Ventre J. J., Guillot M., Confavreux C., Evreux J. C., Aimard G. Les effets indésirables de l'azathioprine (Imurel). A propos de 313 malades traités pour une sclérose en plaques. Revue de la littérature. Therapie. 1985 May-Jun;40(3):195–202. [PubMed] [Google Scholar]
  36. Weiner H. L., Mackin G. A., Matsui M., Orav E. J., Khoury S. J., Dawson D. M., Hafler D. A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26;259(5099):1321–1324. doi: 10.1126/science.7680493. [DOI] [PubMed] [Google Scholar]
  37. Weiner H. L., Mackin G. A., Orav E. J., Hafler D. A., Dawson D. M., LaPierre Y., Herndon R., Lehrich J. R., Hauser S. L., Turel A. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 May;43(5):910–918. doi: 10.1212/wnl.43.5.910. [DOI] [PubMed] [Google Scholar]
  38. Weinshenker B. G., Rice G. P., Noseworthy J. H., Carriere W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain. 1991 Apr;114(Pt 2):1057–1067. doi: 10.1093/brain/114.2.1057. [DOI] [PubMed] [Google Scholar]
  39. Willoughby E. W., Paty D. W. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988 Nov;38(11):1793–1798. doi: 10.1212/wnl.38.11.1793. [DOI] [PubMed] [Google Scholar]
  40. Yudkin P. L., Ellison G. W., Ghezzi A., Goodkin D. E., Hughes R. A., McPherson K., Mertin J., Milanese C. Overview of azathioprine treatment in multiple sclerosis. Lancet. 1991 Oct 26;338(8774):1051–1055. doi: 10.1016/0140-6736(91)91909-e. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES